Nxera Pharma Co., Ltd. (4565) Stock Price

Nexera Pharma is a technology-driven biopharmaceutical company aiming to address unmet medical needs in Japan and worldwide. The company focuses on core business activities spanning drug discovery, development, and commercialization, with the goal of providing innovative specialty pharmaceuticals that improve patients' quality of life.

Nexera Pharma's business consists of a single segment: "Pharmaceutical Business." Nxera Pharma UK Limited, a UK-based subsidiary, is responsible for drug discovery, translational medicine, and preclinical and early-stage clinical development. Nexera Pharma Japan Co., Ltd. and Nxera Pharma Korea Co., Ltd. primarily handle clinical development and commercialization in Japan and Korea, respectively.

Nexera Pharma Co., Ltd. conducts pharmaceutical research and development, import/export, contract manufacturing, and sales. The company also provides strategic planning for group management and undertakes administrative functions for subsidiary management. Nexera Pharma Japan Co., Ltd. is responsible for pharmaceutical research and development, import/export, packaging, and sales.

Nxera Pharma UK Limited conducts structural analysis of GPCRs, generates initial lead compounds, and identifies drug candidates using its proprietary NxStaR technology. Through these activities, the company advances the development of innovative pharmaceuticals.

Nexera Pharma is a technology-driven biopharmaceutical company committed to addressing unmet medical needs in Japan and worldwide. The company's core business encompasses the research, development, and commercialization of innovative specialty pharmaceuticals designed to improve patients' quality of life.

The company's growth strategy focuses on leveraging its proprietary NxWave™ platform, a GPCR structure-based drug discovery technology, to create innovative new medicines. The company maintains a pipeline of over 30 programs targeting key therapeutic areas including neurological and immunological diseases, with potential to become first-in-class or best-in-class treatments.

Nexera Pharma is advancing clinical development and commercialization in Japan and the APAC region, aiming to bring new medicines to patients in the growing Japanese market. The company also relies on royalty income from global sales of Novartis respiratory disease products as a significant capital source.

Following a name change in 2024, the company has evolved its strategy. Key pillars include delivering innovative medicines to Japanese patients and advancing high-value programs created through drug design innovation. The company aims to accelerate innovation by leveraging cutting-edge science and technology.

Nexera Pharma is pursuing an efficient business model to adapt to industry changes and create sustainable business opportunities. The company is also strengthening its corporate governance framework and promoting a corporate culture that emphasizes transparency and accountability.